Regeneron Pharmaceuticals plans to expand its pipeline into radiopharmaceutical therapies through an up to $4.3 billion collaboration with Telix Pharmaceuticals to co-develop and co-commercialize ...

Regeneron Pharmaceuticals REGN announced that it has entered into a strategic collaboration with Telix Pharmaceuticals ...

The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses.

Regeneron and Telix join forces in a 50/50 collaboration to develop and commercialize next-gen radiopharmaceuticals, ...

SpectronRx secures $85M from OrbiMed to expand medical isotope production, boosting radiopharmaceutical manufacturing and ...

Financial terms include $40 million upfront for four programs, expansion options, and opt-out economics up to $535 million per program plus low double-digit royalties, totaling up to $2.1 billion.

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has entered into a strategic collaboration with Telix Pharmaceuticals (NASDAQ:TLX) to ...

Drug developers weigh building internal radiopharmaceutical capabilities versus outsourcing amid timeline and funding uncertainties in the sector.

SpectronRx raises $85M to expand radiopharmaceutical production, boosting supply and access to advanced nuclear medicine treatments.

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix’s expertise in ...

European authorities have recommended changes to the regulatory framework to keep pace with the progress of the ...